Bruton tyrosine kinase inhibitors: A promising novel targeted treatment for B cell lymphomas

British Journal of Haematology

Volumn 163, Issue 4, 2013, Pages 436-443

  Aalipour, Amin ^a   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell receptor signalling; Bruton tyrosine kinase; CC 292; Ibrutinib; Refractory non Hodgkin lymphoma

Indexed keywords

2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; ASPARAGINASE; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BRUTON TYROSINE KINASE INHIBITOR; CC 292; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DASATINIB; FLUDARABINE; IBRUTINIB; LENALIDOMIDE; METHYLPREDNISOLONE; OFATUMUMAB; ONO WG 307; PLACEBO; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; ARTHRITIS; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GRAFT FAILURE; HUMAN; IC 50; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG EDEMA; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS;

B CELL RECEPTOR SIGNALLING; BRUTON TYROSINE KINASE; CC-292; IBRUTINIB; REFRACTORY NON-HODGKIN LYMPHOMA;

ANIMALS; HUMANS; LYMPHOMA, B-CELL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84886386342     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12573     Document Type: Review

References (43)

1. Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., Kolibaba, K.S., Furman, R.R., Rodriguez, S., Chang, B.Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E. & Fowler, N.H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 88-94.
2. Amrein, P.C., Attar, E.C., Takvorian, T., Hochberg, E.P., Ballen, K.K., Leahy, K.M., Fisher, D.C., LaCasce, A.S., Jacobsen, E.D., Armand, P., Hasserjian, R.P., Werner, L., Neuberg, D. & Brown, J.R. (2011) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research, 17, 2977-2986.
3. Brown, J.R. (2012) Ibrutinib (PCI-32765), the first BTK (Bruton's Tyrosine Kinase) inhibitor in clinical trials. Current Hematologic Malignancy Reports, 8, 1-6.
4. Brown, J.R. (2013) Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leukemia and Lymphoma, doi: 10.3109/10428194.2013.803226.
5. Brown, J.R., Sharman, J.P., Harb, W.A., Kelly, K.R., Schreeder, M.T., Sweetenham, J.W., Barr, P.M., Foran, J.M., Gabrilove, J.L., Kipps, T.J., Ma, S., O'Brien, S.M., Evans, E., Lounsbury, H., Silver, B.A., Singh, J., Stiede, K., Westlin, W., Witowski, S. & Mahadevan, D. (2012a) Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)[abstract]. Journal of Clinical Oncology(ASCO meeting abstracts), 30, 8032.
6. Brown, J.R., Barrientos, J., Flinn, I., Barr, P., Burger, J., Navarro, T., James, D., Hedrick, E., Friedberg, J. & Brown, J.R. (2012b) The Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/II study [abstract]. Haematologica, 97, 0543.
7. Brown, J., Harb, W., Sharman, J., Hill, B., Ma, S., Miller, T., Schreeder, M., Barr, P., Foran, J., Gabrilove, J., Kelly, K., Burger, J., Barnett, E., Marine, J., Nava-Parada, P., Azaryan, A., Mei, J. & Kipps, T. (2013) Phase 1 study of single agent cc-292, a highly selective bruton's tyrosine kinase (btk) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (b-NHL) [abstract]. Haematologica, 98, S520.
8. Burger, J.A. & Buggy, J.J. (2013) Emerging Drug Profiles: bruton tyroine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leukemia and Lymphoma, doi: 10.3109/10428194.2013.777837.
9. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Sharman, J.P., Grant, B., Jones, J.A., Wierda, W.G., Zhao, W., Heerema, N.A., Johnson, A.J., Tran, A., Clow, F., Kunkel, L., James, D.F. & O'Brien, S. (2012a) The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study [abstract]. Blood (ASH Annual Meeting Abstracts), 120, 189.
10. Byrd, J.C., Furman, R.R., Coutre, S.E., Burger, J.A., Blum, K.A., Sharman, J.P., Flinn, I.W., Grant, B.W., Heerema, N.A., Johnson, A.J., Navarro, T., James, D.F., Hedrick, E. & O'Brien, S.M. (2012b) The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II study [abstract]. Journal of Clinical Oncology (ASCO meeting abstracts), 30, 6507.
11. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F. & O'Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine, 369, 32-42.
12. Chen, L., Monti, S., Juszczynski, P., Daley, J., Chen, W., Witzig, T.E., Habermann, T.M., Kutok, J.L. & Shipp, M.A. (2008) SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood, 111, 2230-2237.
13. Dal Porto, J.M., Gauld, S.B., Merrell, K.T., Mills, D., Pugh-Bernard, A.E. & Cambier, J. (2004) B cell antigen receptor signaling 101. Molecular Immunology, 41, 599-613.
14. Davids, M.S. & Brown, J.R. (2012) Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leukemia and Lymphoma, 53, 2362-2370.
15. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
16. Dühren-von Minden, M., Übelhart, R., Schneider, D., Wossning, T., Bach, M.P., Buchner, M., Hofmann, D., Surova, E., Follo, M., Köhler, F., Wardemann, H., Zirlik, K., Veelken, H. & Jumaa, H. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature, 489, 309-312.
17. Evans, E., Tester, R., Aslanian, S., Chaturvedi, P., Mazdiyasni, H., Ponader, S., Tesar, B., Sheets, M., Nacht, M., Stiede, K., Witowski, S., Lounsbury, H., Petter, R., Brown, J.R., Burger, J.A., Singh, J. & Westlin, W.F. (2011) Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies [abstract]. Blood (ASH Annual Meeting Abstracts), 118, 3485.
18. Evans, E.K., Tester, R., Aslanian, S., Karp, R., Sheets, M., Labenski, M.T., Witowski, S.R., Lounsbury, H., Chaturvedi, P., Mazdiyasni, H., Zhu, Z., Nacht, M., Freed, M.I., Petter, R.C., Dubrvskiy, A., Singh, J. & Westlin, W.F. (2013) Inhibition of Btk with CC-292 Provides early pharmacodynamic assessment of activity in mice and humans. Journal of Pharmacology and Experimental Therapeutics, 346, 219-228.
19. Fowler, N.H., Advani, R.H., Sharman, J.P., Smith, S.M., McGreivy, J., Kunkel, L., Truong, V., Zhou, C. & Boyd, T.E. (2012) The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts), 120, 156.
20. Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K.L., Ellmeier, W., Valent, P. & Superti-Furga, G. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences, 104, 13283-13288.
21. Herman, S.E., Gordon, A.L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K.A., Buggy, J.J., Hamdy, A., Johnson, A.J. & Byrd, J.C. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood, 117, 6287-6296.
22. Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences, 107, 13075-13080.
23. Jaglowski, S.M., Jones, J.A., Flynn, J.M., Andritsos, L.A., Maddocks, K.J., Blum, K.A., Grever, M.R., Geyer, S.M., Woyach, J.A., Johnson, A.J., Heerema, N.A., Molnar, E., Stefanos, M., Devlin, S., Navarro, T., James, D.F., Lowe, A.M., Hedrick, E. & Byrd, J.C. (2012) A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases [abstract]. Journal of Clinical Oncology (ASCO Annual Meeting Abstracts), 30, 6508.
24. Kozaki, R., Yoshizawa, T., Tohda, S., Yasuhiro, T., Hotta, S., Ariza, Y., Ueda, Y., Narita, M. & Kawabata, K. (2011) Development of a Bruton's tyrosine kinase (Btk) Inhibitor, ONO-WG-307: efficacy in ABC-DLBCL xenograft model - potential treatment for B-cell malignancies [abstract]. Blood (ASH Annual Meeting Abstracts), 118, 3731.
25. Kozaki, R., Yoshizawa, T., Yashuhiro, T., Mirjolet, J., Birkett, J., Narita, M. & Kawabata, K. (2012) Development of a Bruton's tyrosine kinase (Btk) inhibitor - ONO-WG-307, a potential treatment for B-cell malignancies [abstract]. Cancer Research, 72, 857.
26. Maas, A. & Hendriks, R.W. (2001) Role of Bruton's tyrosine kinase in B cell development. Developmental Immunology, 8, 171-181.
27. Mahajan, S., Ghosh, S., Sudbeck, E.A., Zheng, Y., Downs, S., Hupke, M. & Uckun, F.M. (1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. The Journal of Biological Chemistry, 274, 9587-9599.
28. Monroe, J.G. (2006) ITAM-mediated tonic signaling through pre-BCR and BCR complexes. Nature Reviews Immunology, 6, 283-294.
29. Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., Shaffer, A.L., Romesser, P., Wright, G., Powell, J., Rosenwald, A., Muller-Hermelink, H.K., Ott, G., Gascoyne, R.D., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C. & Staudt, L.M. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature, 470, 115-119.
30. Pollyea, D.A., Smith, S., Fowler, N., Boyd, T.E., Smith, A.M., Sirisawad, M., Honigberg, L.A., Hamdy, A. & Advani, R.H. (2009) A phase I dose escalation study of the BtkInhibitor PCI-32765 in relapsed and refractory B cell non-Hodgkin Lymphoma and use of a novel fluorescent probe pharmacodynamic assay [abstract]. Blood, 114, 3713.
31. Ponader, S., Chen, S.S., Buggy, J.J., Balakrishnan, K., Gandhi, V., Wierda, W.G., Keating, M.J., O'Brien, S., Chiorazzi, N. & Burger, J.A. (2012) Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119, 1182-1189.
32. Rinaldi, A., Kwee, I., Taborelli, M., Largo, C., Uccella, S., Martin, V., Poretti, G., Gaidano, G., Calabrese, G., Martinelli, G., Baldini, L., Pruneri, G., Capella, C., Zucca, E., Cotter, F.E., Cigudosa, J.C., Catapano, C.V., Tibiletti, M.G. & Bertoni, F. (2006) Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal of Haematology, 132, 303-316.
33. Robak, T. & Robak, P. (2013) BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. International Reviews of Immunology, 32, 358-376.
34. de Rooij, M.F., Kuil, A., Geest, C.R., Eldering, E., Chang, B.Y., Buggy, J.J., Pals, S.T. & Spaargaren, M. (2012) The clinical active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 119, 2590-2594.
35. Steinberg, M. (2007) Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical Therapeutics, 29, 2289-2308.
36. Uckun, F.M., Zheng, Y., Cetkovic-Cvrlje, M., Vassilev, A., Lisowski, E., Waurzyniak, B., Chen, H., Carpenter, R. & Chen, C.L. (2002) In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2, 5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clinical Cancer Research, 8, 1224-1233.
37. Uckun, F., Dibirdik, I., Sarkissian, A. & Qazi, S. (2011) In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. Arzneimittel-Forschung, 61, 252-259.
38. Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. & Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England Journal of Medicine, 369, 507-516.
39. Wiestner, A. (2012) Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood, 120, 4684-4691.
40. Wiestner, A. (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. Journal of Clinical Oncology, 31, 128-130.
41. William, B.M., Hohenstein, M., Loberiza, F.R. Jr, Caponetti, G.C., Bociek, R.G., Bierman, P., Armitage, J.O., Chan, W. & Vose, J.M. (2010) Phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts), 116, 288.
42. Wilson, W.H., Gerecitano, J.F., Goy, A., de Vos, S., Kenkre, V.P., Barr, P.M., Blum, K.A., Shustov, A.R., Advani, R.H., Lih, J., Williams, M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Kunkel, L.A., McGrievy, J., Balasubramanian, S., Cheng, M., Moussa, D., Buggy, J.J. & Staudt, L.M. (2012) The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood (ASH Annual Meeting Abstracts), 120, 686.
43. Yasuhiro, T., Yoshizawa, T., Daub, H., Weber, C., Narita, M. & Kawabata, K. (2012) ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways [abstract]. Cancer Research, 72, 2021.